Compare CUK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUK | BIIB |
|---|---|---|
| Founded | 1972 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 27.1B |
| IPO Year | N/A | 1996 |
| Metric | CUK | BIIB |
|---|---|---|
| Price | $25.34 | $184.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 27 |
| Target Price | $35.57 | ★ $195.00 |
| AVG Volume (30 Days) | ★ 2.8M | 730.4K |
| Earning Date | 03-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.62% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.79 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | $8.05 | N/A |
| Revenue Next Year | $4.08 | N/A |
| P/E Ratio | ★ $16.36 | $20.61 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $13.65 | $110.04 |
| 52 Week High | $33.72 | $202.41 |
| Indicator | CUK | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 48.67 |
| Support Level | $23.26 | $181.24 |
| Resistance Level | $27.88 | $191.60 |
| Average True Range (ATR) | 1.02 | 4.53 |
| MACD | -0.10 | -0.70 |
| Stochastic Oscillator | 32.81 | 31.95 |
Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Line, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard in the United Kingdom; Aida in Germany; and Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 14 million guests in 2025.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).